These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 22124099)

  • 21. Comparing two arsenic trioxide administration methods in APL therapy.
    Zhou J; Meng R; Yang BF
    Chin Med J (Engl); 2004 Sep; 117(9):1411-3. PubMed ID: 15377438
    [No Abstract]   [Full Text] [Related]  

  • 22. [Arsenic trioxide, a new drug for the treatment of acute promyelocytic leukemia resistant to tretinoine].
    Haanen C; Vermes I
    Ned Tijdschr Geneeskd; 1999 Aug; 143(34):1738-41. PubMed ID: 10494320
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Successful pregnancy after arsenic trioxide therapy for relapsed acute promyelocytic leukaemia.
    Ammatuna E; Cavaliere A; Divona M; Amadori S; Scambia G; Lo-Coco F
    Br J Haematol; 2009 Aug; 146(3):341. PubMed ID: 19545283
    [No Abstract]   [Full Text] [Related]  

  • 24. Scientists explore use of arsenic in therapy.
    Miller M
    J Natl Cancer Inst; 1998 Dec; 90(24):1866-7. PubMed ID: 9862622
    [No Abstract]   [Full Text] [Related]  

  • 25. Evidence for basophilic differentiation of acute promyelocytic leukaemia cells during arsenic trioxide therapy.
    Masamoto Y; Nannya Y; Arai S; Koike Y; Hangaishi A; Yatomi Y; Kurokawa M
    Br J Haematol; 2009 Mar; 144(5):798-9. PubMed ID: 19036092
    [No Abstract]   [Full Text] [Related]  

  • 26. Elemental arsenic entered the cerebrospinal fluid during oral arsenic trioxide treatment of meningeal relapse of acute promyelocytic leukemia.
    Au WY; Tam S; Fong BM; Kwong YL
    Blood; 2006 Apr; 107(7):3012-3. PubMed ID: 16554490
    [No Abstract]   [Full Text] [Related]  

  • 27. A single course of all-trans retinoic acid plus arsenic trioxide reached a long-term survival in a patient with newly diagnosed acute promyelocytic leukemia: a suggestion for reduction of treatment courses?
    Yan J; Chen X; Shao J
    Eur J Haematol; 2013 Nov; 91(5):470-1. PubMed ID: 23869721
    [No Abstract]   [Full Text] [Related]  

  • 28. Prognostic significance of additional cytogenetic abnormalities and FLT3 mutations in acute promyelocytic leukemia.
    Dillon R; Grimwade D
    Leuk Lymphoma; 2014 Jul; 55(7):1444-6. PubMed ID: 24313832
    [No Abstract]   [Full Text] [Related]  

  • 29. [Research advances on effect of arsenic trioxide on tumor].
    Feng CQ; Ma WL; Zheng WL
    Ai Zheng; 2002 Dec; 21(12):1386-9. PubMed ID: 12520754
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Arsenic in the cerebrospinal fluid of a patient receiving arsenic trioxide for relapsed acute promyelocytic leukemia with CNS involvement.
    Knipp S; Gattermann N; Schapira M; Käferstein H; Germing U
    Leuk Res; 2007 Nov; 31(11):1585-7. PubMed ID: 17416415
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Arsenic trioxide in the treatment of acute promyelocytic leukaemia].
    Ercilla Liceaga M; Andueza Granados K; Fernández González I; Barcia Romero MJ
    Farm Hosp; 2003; 27(2):93-100. PubMed ID: 12717564
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Non-lethal bone marrow necrosis under first-line arsenic trioxide therapy in acute promyelocytic leukaemia.
    Ianotto JC; Tempescul A; Eveillard JR; Charles F; Berthou C
    Acta Haematol; 2010; 123(3):146-7. PubMed ID: 20134156
    [No Abstract]   [Full Text] [Related]  

  • 33. Unusual sites of involvement by hematologic malignancies. Case 3. External auditory canal tumor: a rare chloroma in acute promyelocytic leukemia with a complete response to arsenic trioxide.
    Au WY; Chan GC; Chim CS; Shek TW; Ooi GC; Ho WK; Kwong YL
    J Clin Oncol; 2001 Oct; 19(19):3993-5. PubMed ID: 11579122
    [No Abstract]   [Full Text] [Related]  

  • 34. Clinical efficacy of arsenic trioxide in a patient with acute promyelocytic leukemia with recurrent central nervous system involvement.
    Zappasodi P; Rossi M; Ambaglio I; Bernasconi P; Corso A; Lazzarino M; Castagnola C
    Ann Hematol; 2011 May; 90(5):595-7. PubMed ID: 20721555
    [No Abstract]   [Full Text] [Related]  

  • 35. Two cases of monocular visual loss during oral arsenic trioxide therapy of acute promyelocytic leukemia.
    Au WY; Hon C; Yau K; Lai WW; Fong BM; Tam S; Kwong YL
    Am J Hematol; 2009 Oct; 84(10):699. PubMed ID: 19705432
    [No Abstract]   [Full Text] [Related]  

  • 36. Central nervous system relapse in a patient with acute promyelocytic leukaemia treated with arsenic tri-oxide.
    Mathews V; Balasubramanian P; Shaji RV; George B; Chandy M; Srivastava A
    Br J Haematol; 2001 Apr; 113(1):257-8. PubMed ID: 11360894
    [No Abstract]   [Full Text] [Related]  

  • 37. Treatment of acute promyelocytic leukemia with arsenic trioxide.
    Tamm I; Paternostro G; Zapata JM
    N Engl J Med; 1999 Apr; 340(13):1043; author reply 1044-5. PubMed ID: 10189285
    [No Abstract]   [Full Text] [Related]  

  • 38. New data with arsenic trioxide in leukemias and myelodysplastic syndromes.
    Sekeres MA
    Clin Lymphoma Myeloma; 2007 Dec; 8 Suppl 1():S7-S12. PubMed ID: 18282365
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of acute promyelocytic leukemia with arsenic trioxide.
    Conrad ME
    N Engl J Med; 1999 Apr; 340(13):1043-5. PubMed ID: 10189286
    [No Abstract]   [Full Text] [Related]  

  • 40. Pseudotumor cerebri after treatment of relapsed acute promyelocytic leukemia with arsenic trioxide.
    Galm O; Fabry U; Osieka R
    Leukemia; 2000 Feb; 14(2):343-4. PubMed ID: 10673758
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.